Given the established involvement of PAK signalling in angiogenesis and immune regulation [14], we have further determined the effects of PAK1 and PAK4 on tumour vasculature in PDA, and their impact on therapeutic outcomes. The gene discussed is PAK4; the disease is Patent ductus arteriosus.